Literature DB >> 18028389

High prevalence of undiagnosed patients with peripheral arterial disease in patients hospitalised for non-vascular disorders.

P Lacroix1, V Aboyans, D Voronin, A Le Guyader, M Cautrès, M Laskar.   

Abstract

BACKGROUND: Several studies highlight the underestimation of peripheral arterial disease (PAD) rates in general population, leading to a lack of opportunity to detect subjects at a high risk for cardiovascular events. We sought to investigate (i) the prevalence of unrecognised PAD in patients hospitalised for non-vascular diseases and (ii) the intensity of preventive drug therapies in this population. DESIGN AND METHODS: This study was of the cross-sectional design in a tertiary care hospital, which included 291 randomly selected patients of >or=40 years of age. Patients were assessed for medical history, pulse palpation and ankle-brachial index (ABI). The Edinburgh Claudication Questionnaire (ECQ) was administered. PAD was defined either by an ABI<or=0.9 or>or=1.4 or in case of limb revascularisation history.
RESULTS: Overall PAD prevalence was 29%; 21 patients (7.2%) with a history of PAD, while 65 (22.3%) had an unknown PAD. Among patients with unknown PAD, a typical intermittent claudication was unusual (3%). In patients without cardiovascular disease (CVD), four factors were associated with unrecognised PAD: absence of posterior tibial pulse (OR 4.49, 95% CI 1.89-10.51; p<0.001), male sex (OR 2.32, 95% CI 1.03-5.25; p=0.04), age>70 years (OR 2.44, 95% CI 1.07-5.58; p=0.04), CVD risk factors>or=2 (OR 2.63, 95% CI 1.20-5.76; p=0.02). Antiplatelet therapy and statins were each prescribed in 35.5% of the unrecognised PAD patients with ABI<or=0.9 and 25.8% of those with ABI>or=1.4.
CONCLUSIONS: In a tertiary care hospital, the prevalence of unrecognised PAD among patients hospitalised for non-PAD-related causes is high and the preventive CVD therapy rates are low. Hospitalisation is a good opportunity to detect PAD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18028389     DOI: 10.1111/j.1742-1241.2007.01579.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  6 in total

1.  The silent overall burden of foot disease in a representative hospitalised population.

Authors:  Peter A Lazzarini; Sheree E Hurn; Suzanne S Kuys; Maarten C Kamp; Vanessa Ng; Courtney Thomas; Scott Jen; Jude Wills; Ewan M Kinnear; Michael C d'Emden; Lloyd F Reed
Journal:  Int Wound J       Date:  2016-10-03       Impact factor: 3.315

Review 2.  Methods of symptom evaluation and their impact on peripheral artery disease (PAD) symptom prevalence: a review.

Authors:  Erica N Schorr; Diane Treat-Jacobson
Journal:  Vasc Med       Date:  2013-03-18       Impact factor: 3.239

3.  Foot Complications in a Representative Australian Inpatient Population.

Authors:  Peter A Lazzarini; Sheree E Hurn; Suzanne S Kuys; Maarten C Kamp; Vanessa Ng; Courtney Thomas; Scott Jen; Jude Wills; Ewan M Kinnear; Michael C d'Emden; Lloyd F Reed
Journal:  J Diabetes Res       Date:  2017-10-15       Impact factor: 4.011

Review 4.  Diabetes-related foot disease in Australia: a systematic review of the prevalence and incidence of risk factors, disease and amputation in Australian populations.

Authors:  Yuqi Zhang; Jaap J van Netten; Mendel Baba; Qinglu Cheng; Rosana Pacella; Steven M McPhail; Susanna Cramb; Peter A Lazzarini
Journal:  J Foot Ankle Res       Date:  2021-01-19       Impact factor: 2.303

5.  Predicting Future Cardiovascular Events in Patients With Peripheral Artery Disease Using Electronic Health Record Data.

Authors:  Elsie Gyang Ross; Kenneth Jung; Joel T Dudley; Li Li; Nicholas J Leeper; Nigam H Shah
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2019-03

Review 6.  Prevalence of foot disease and risk factors in general inpatient populations: a systematic review and meta-analysis.

Authors:  Peter A Lazzarini; Sheree E Hurn; Malindu E Fernando; Scott D Jen; Suzanne S Kuys; Maarten C Kamp; Lloyd F Reed
Journal:  BMJ Open       Date:  2015-11-23       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.